Ketamine Infusion Therapy Cost in Alaska

Ketamine Infusion Therapy in Alaska costs $413 to $1,003 in 2026, with a state-wide median of $620. Pricing varies by metro - typically $620 in Anchorage and $620 in Anchorage. Alaska pricing is 18% above the national average.

Anchorage typically has the lowest ketamine infusion therapy pricing in Alaska, with a median of $620 (1.18x national average). Mid-size markets generally run lower than major coastal or wealthy suburban areas.

Anchorage typically has the highest ketamine infusion therapy pricing in Alaska, with a median of $620 (1.18x national average). Larger metro areas with higher cost of living and more specialty providers tend to command premium pricing.

IV ketamine is rarely covered by US insurance because it is used off-label. Spravato (FDA-approved esketamine) has insurance coverage pathways with prior authorization. For patients seeking insurance-covered ketamine treatment, Spravato is typically the financial path.

Alaska pricing is 18% above the national average. The state cost index is 1.18x the national average. Higher-cost states include California, New York, Massachusetts, and Washington DC; lower-cost states include Oklahoma, Mississippi, Kentucky, and Indiana.

The standard 6-infusion induction protocol typically runs $2,400 to $5,100 total in the US, with a median around $3,000. Per-infusion cost is $350-$850 depending on location and provider. Maintenance infusions afterward run $350-$850 each at variable frequency (every 2-8 weeks typical).

Most US insurance does not cover off-label IV ketamine. Spravato (the FDA-approved esketamine nasal spray) is more frequently covered with prior authorization. For patients with treatment-resistant depression seeking insurance-covered options, Spravato is typically the better financial path. Some HSA/FSA funds can be used for IV ketamine as qualified medical expense when prescribed for a documented diagnosis.

Standard induction is 6 infusions over 2-3 weeks (typically 2-3 per week). Maintenance varies widely by patient response. Common patterns: 1 infusion every 2 weeks initially, gradually extending to every 4-8 weeks as response is sustained. Some patients achieve remission and discontinue maintenance entirely.

Acute antidepressant effects from a single infusion typically last 1-2 weeks. Full induction series produces benefit lasting 2-4 months for many responders. Sustained response often requires ongoing maintenance infusions, similar to how diabetes is managed with ongoing medication rather than cured.

IV ketamine at sub-anesthetic therapeutic doses in a clinical setting has a strong safety profile when properly administered. Common short-term effects include dissociation (expected), transient blood pressure elevation, nausea (10-15%), and grogginess. Serious complications are rare. Abuse risk is low in controlled clinical setting. Long-term high-frequency maintenance carries some bladder dysfunction risk.